Patents Examined by Ginny Allen Portner
  • Methods for treating cardiovascular diseases with botulinum toxin
    Patent number: 6767544
    Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: July 27, 2004
    Assignee: Allergan, Inc.
    Inventors: Gregory F. Brooks, Stephen Donovan
  • Use of echinacea as a feed additive to enhance protection against coccidiosis
    Patent number: 6767546
    Abstract: Echinacea dietary supplements are useful adjuvants for live anticoccidial vaccines. Feed supplementation with Echinacea preparations enhances the immune response to such vaccines. Echinacea purpurea in amounts of about 0.1% to 0.5% administered for about two weeks to day-old chicks has been found effective for providing significant weight gain compared to vaccination alone.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: July 27, 2004
    Assignees: The United States of America as represented by the Secretary of Agriculture, Triarco Industries, Inc.
    Inventors: Patricia C. Allen, Mark Anderson, Harry D. Danforth
  • Methods of inhibiting helicobacter pylori
    Patent number: 6762051
    Abstract: This invention relates to methods of screening molecules capable of inhibiting the survival of Helicobacter pylori in vivo by specifically inhibiting the activity of UreI, to the molecules identified by these methods, and to the use of these molecules to treat or prevent H. pylori infection.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: July 13, 2004
    Assignee: Institut Pasteur
    Inventors: Hilde De Reuse, Stéphane Skouloubris, Valérie Cussac, Agnés Labigne
  • Protective helicobacter antigens
    Patent number: 6762295
    Abstract: Protective Helicobacter antigens, especially H. pylori antigens, and the use of these antigens for the treatment of or prevention of, gastroduodenal disease associated with H. pylori infection.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: July 13, 2004
    Assignees: CSL Limited, The University of New South Wales
    Inventors: Christopher Vincent Doidge, Adrian Lee, Fiona Jane Radcliff, Dianna Margaret Hocking, Elizabeth Ann Webb
  • Enterococcus antigens and vaccines
    Patent number: 6756361
    Abstract: A majority of E. faecalis and E. faecium clinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of E. faecalis and E. faecium, and can elicit production of protective antibodies. Accordingly, the antigens are useful for vaccines which protect against infection by clinically significant (pathogenic) Enterococcus isolates. The antigens and antibodies generated to the antigens are also useful in diagnostic assays.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: June 29, 2004
    Assignee: NABI
    Inventors: Ali Ibrahim Fattom, Ramesh K. Sood, Sara E. Shepherd
  • Method of detecting cardiac ischemia using fatty acid binding protein
    Patent number: 6750030
    Abstract: A method of detecting cardiac ischemia by detecting elevated levels of serum free fatty acids in serum unbound to serum albumin (FFAU) compared to an average FFAU level in individuals without cardiac ischemia, wherein the detection method uses a free fatty acid binding protein derivatized with a fluorescent moiety, is disclosed.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: June 15, 2004
    Assignee: Torrey Pines Institute for Molecular Studies
    Inventor: Alan M. Kleinfeld
  • Advanced glycation end-product intermediaries and post-amadori inhibition
    Patent number: 6750209
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: June 15, 2004
    Assignee: Kansas University Medical Center
    Inventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
  • Adjuvants for use in vaccines
    Patent number: 6733754
    Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: May 11, 2004
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
  • Compositions and methods for regulating bacterial pathogenesis
    Patent number: 6720415
    Abstract: This invention provides a purified extracellular bacterial autoinducer-2 signaling molecule, the production of which is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. The signaling molecule stimulates LuxQ luminescence genes, and is believed also to stimulate a variety of pathogenesis related genes in the bacterial species that produce it. This invention also provides is a new class of bacterial genes involved in the biosynthesis of the signaling molecule.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: April 13, 2004
    Assignees: Princeton University, University Technologies International
    Inventors: Bonnie L. Bassler, Michael G. Surette
  • Proteins from actinobacillus pleuropneumoniae
    Patent number: 6713071
    Abstract: The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: March 30, 2004
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Robert G. Ankenbauer, Mary Jo Baarsch, Manuel Campos, Robin Keich, Everett Rosey, Brian Suiter, Lynn Warren-Stewart
  • Helicobacter pylori adhesin binding group antigen
    Patent number: 6709656
    Abstract: A novel blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to Helicobacter pylori fucosylated blood group antibodies. Said adhesin has a molecular weight of about 73.5 kDa and the N-terminal sequence for the adhesin and the corresponding DNA show homologies between different strains of H. pylori. Said adhesin and/or DNA is useful for diagnose and therapy and/or profylax directed against H. pylori induced infections, e.g. gastritis and acid peptic disease.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 23, 2004
    Inventors: Thomas Boren, Anna Arnqvist, Lennart Hammarstrom, Staffan Normark, Dag Ilver
  • Lipopolysaccharide &agr;-2,3 sialytransferase of campylobacter jejuni and its uses
    Patent number: 6709834
    Abstract: The structure and specificity of a recombinant &agr;2,3-sialyltransferase from Campylobacter spp., is disclosed. Also provided are methods for using the &agr;2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: March 23, 2004
    Assignee: National Research Council of Canada
    Inventors: Michel Gilbert, Warren W. Wakarchuk
  • Method for screening the risk of gastric cancer
    Patent number: 6696262
    Abstract: Method for screening the risk for gastric cancer using, in combination, the determination of serum pepsinogen I, gastrin-17 and the supporting determination of Helicobacter pylori antibodies from blood serum, in order to detect either atrophy of the corpus area, atrophy of the antrum area or atrophy of the mucosa of the whole stomach as well as a causative Helicobacter pylori infection, whereby the risk for gastric cancer can be evaluated and the necessary gastroscopy and follow-up can be planned.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: February 24, 2004
    Assignee: Biohit Oyj
    Inventor: Matti Härkönen
  • Biosensor
    Patent number: 6692696
    Abstract: Apparatus comprising G-protein coupled receptor (GPCR) for detecting ligands or substances in liquid or vapor media. The GPCR is based on in a cell or in a synthetic membrane or polymer system, and combined with means for obtaining a sample of a liquid or vapor medium, and with automatic optical detection system and monitoring system for detecting a ligand of interest. Methods are disclosed for detecting a ligand of interest using the GPCR apparatus.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: February 17, 2004
    Assignee: Areté Associates
    Inventor: Randall S. Alberte
  • Method for diagnosing bone dysbolism
    Patent number: 6693175
    Abstract: A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10−7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: February 17, 2004
    Assignee: Sankyo Co., Ltd.
    Inventors: Kazuki Yano, Fumie Kobayashi, Masaaki Goto, Naohiro Washida, Eisuke Tsuda, Kanji Higashio, Yoshiji Yamada
  • Staphylococcal immunotherapeutics via donor selection and donor stimulation
    Patent number: 6692739
    Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: February 17, 2004
    Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of The College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
  • Lipopolysaccharide &agr;-2,3 sialyltransferase of Campylobacter jejuni and its uses
    Patent number: 6689604
    Abstract: The structure and specificity of a recombinant &agr;2,3-sialyltransferase from Campylobacter spp., is disclosed. Also provided are methods for using the &agr;2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: February 10, 2004
    Assignee: National Research Council of Canada
    Inventors: Michel Gilbert, Warren W. Wakarchuk
  • Peptides representing epitopic sites on r-IFN-&bgr;, antibodies thereto and uses thereof
    Patent number: 6682896
    Abstract: The present invention discloses synthetic peptides and antibodies raised thereto wherein the synthetic peptides represent important epitopic sites recognized by monoclonal antibodies which can neutralize IFN-&bgr;. Also, the uses of these peptides or antibodies thereto as diagnostics and therapeutics are disclosed.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 27, 2004
    Assignee: Schering Aktiengesellschaft
    Inventor: Paul D. Hoeprich, Jr.
  • Invaplex from gram negative bacteria, method of purification and methods of use
    Patent number: 6680374
    Abstract: Isolated antibodies to Invaplex; novel compositions comprising immunoglobulins directed to invasin proteins and LPS from gram negative bacteria that selectively bind to Invaplex, and do not bind to the individual components of Invaplex.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: January 20, 2004
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Edwin V. Oaks, Kevin Ross Turbyfill
  • Expression of recombinant fusion proteins in attenuated bacteria
    Patent number: 6680182
    Abstract: The invention provides a DNA molecule comprising a promoter sequence operably linked to a DNA sequence encoding first and second proteins linked by a hinge region wherein in that the promoter sequence can be one having activity which is induced in response to a change in the surrounding environment and the first protein can be Tetanus toxin C fragment or one or more epitopes thereof. The invention also provides intermediate molecules having a promoter operably linked to a DNA sequence encoding a first antigenic sequence and a hinge region, and at or adjacent the 3′-end thereof one or more restriction sites for the introduction of a second anti-genic sequence. In addition, the invention provides replicable expression vectors containing the DNA fusion proteins expressed therefrom, bacterial transformed with the vectors and the use of the bacteria, in vaccines.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: January 20, 2004
    Assignee: Acambis Research Limited
    Inventors: Mohammed Anjam Khan, Bernardo Villarreal-Ramos, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan